$Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma$

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma

Abstract Background T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared with chimeric antigen receptor-T cells. TCR-T cell therapy is another active field of cellular immunotherapy for cancer. Methods We previously developed a human...

Full description

Bibliographic Details
Main Authors:	Chenggong Li, Fen Zhou, Jing Wang, Qi Chang, Mengyi Du, Wenjing Luo, Yinqiang Zhang, Jia Xu, Lu Tang, Huiwen Jiang, Lin Liu, Haiming Kou, Cong Lu, Danying Liao, Jianghua Wu, Qiuzhe Wei, Sha Ke, Jun Deng, Cheng Liu, Heng Mei, Yu Hu
Format:	Article
Language:	English
Published:	BMC 2023-01-01
Series:	Journal of Hematology & Oncology
Subjects:	γ/δ TCR-T cells DLBCL Primary CNS lymphoma Relapsed or refractory Cellular immunotherapy
Online Access:	https://doi.org/10.1186/s13045-023-01402-y

Similar Items

Multiply Relapsed Secondary CNS Non-Germinal Center Diffuse Large B-Cell Lymphoma Successfully Treated with CNS-Centric Therapy
by: Fournier LL, et al.
Published: (2023-08-01)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
by: Aurélie Cabannes‐Hamy, et al.
Published: (2018-03-01)

Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy
by: Helmneh M. Sineshaw, et al.
Published: (2024-04-01)

Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
by: Rita Assi, et al.
Published: (2021-03-01)

Neurosurgical Management of Central Nervous System Lymphoma: Lessons Learnt from a Neuro-Oncology Multidisciplinary Team Approach
by: Maria Alexandra Velicu, et al.
Published: (2023-04-01)

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
by: Xuzhao Zhang, et al.
Published: (2022-05-01)

T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update
by: Shalini Balendran, et al.
Published: (2023-10-01)

Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma
by: Hsi-Cheng Chien, et al.
Published: (2023-08-01)

Flow Cytometric Pattern of TCRVδ Subtype Expression Rapidly Identifies γδT Cell Lymphoma
by: Xiao Chen, et al.
Published: (2020-06-01)

Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
by: Maria Cristina Pirosa, et al.
Published: (2024-12-01)

Systematic pattern analyses of Vδ2+ TCRs reveal that shared “public” Vδ2+ γδ T cell clones are a consequence of rearrangement bias and a higher expansion status
by: Lihua Deng, et al.
Published: (2022-09-01)

Corrigendum: Systematic pattern analyses of Vδ2+ TCRs reveal that shared “public” Vδ2+ γδ T cell clones are a consequence of rearrangement bias and a higher expansion status
by: Lihua Deng, et al.
Published: (2022-10-01)

BRIDGING TO TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA
by: Christian Gisselbrecht, et al.
Published: (2016-07-01)

Central Nervous System Relapse in Acute Lymphoblastic Leukemia (Study on 160 cases)
by: Azarm T, et al.
Published: (2005-07-01)

Diagnosis and treatment of diffuse large B-cell lymphoma
by: Ulrich J. M. Mey, et al.
Published: (2012-01-01)

PI3Kδ Forms Distinct Multiprotein Complexes at the TCR Signalosome in Naïve and Differentiated CD4+ T Cells
by: Daisy H. Luff, et al.
Published: (2021-03-01)

Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia
by: Noriharu Nakagawa, et al.
Published: (2022-01-01)

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
by: Jain MD, et al.
Published: (2018-05-01)

Relapsed isolated CNS lymphoma treated with radiotherapy and intrathecal methotrexate followed by high‐dose intravenous methotrexate, rituximab, and temozolomide: A case report
by: Ikhwan Rinaldi, et al.
Published: (2024-03-01)

Clinical prognostic risk analysis and progression factor exploration of primary breast lymphoma
by: Jili Deng, et al.
Published: (2022-12-01)

All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
by: Matthias A. Fante, et al.
Published: (2022-05-01)

The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
by: Diana Campillo-Davo, et al.
Published: (2020-07-01)

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement
by: Antonia Maria S. Müller, et al.
Published: (2019-09-01)

Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas
by: Pavle Krsmanovic, et al.
Published: (2022-05-01)

Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP
by: Mohammad Ma'koseh, et al.
Published: (2023-12-01)

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
by: Alejandro Martín García-Sancho, et al.
Published: (2023-12-01)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
by: D. V. Shevyrev, et al.
Published: (2022-11-01)

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
by: Zhi Pang, et al.
Published: (2023-12-01)

pyTCR: A comprehensive and scalable solution for TCR-Seq data analysis to facilitate reproducibility and rigor of immunogenomics research
by: Kerui Peng, et al.
Published: (2022-10-01)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
by: Jing Ding, et al.
Published: (2022-09-01)

Analysis of tumor-related features of non-small cell lung cancer based on TCR repertoire workflow
by: ZHAO Zhuoming, et al.
Published: (2023-12-01)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
by: Anna Nydegger, et al.
Published: (2021-12-01)

Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy
by: Isabella Elias Yonezawa Ogusuku, et al.
Published: (2024-06-01)

Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell LYMPHOMA: A multi-institution retrospective analysis and systematic review
by: John Xie, et al.
Published: (2021-01-01)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

SwarmTCR: a computational approach to predict the specificity of T cell receptors
by: Ryan Ehrlich, et al.
Published: (2021-09-01)

Autophagic flux restoration of senescent T cells improves antitumor activity of TCR‐engineered T cells
by: Chaoting Zhang, et al.
Published: (2022-01-01)

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
by: Zhang J, et al.
Published: (2023-02-01)

Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
by: Cheng Huang, et al.
Published: (2024-01-01)